Regardless of study design, the approval process of biologics and biological devices cannot identify every possible safety concern.
For the last several years, and looking forward, where there may be little to distinguish biologics medicines with relatively similar efficacy profiles, the biotechnology market is beginning to differentiate products by patient-focused, biologic-device based combination products.
As innovative as biologic-device combination products are, they can pose considerable development, regulatory, and commercialization challenges due to unique physicochemical properties and special clinical considerations (e.g., dosing volumes, frequency, co-medications, etc). of the biologic medicine.
Animal models have been the mainstay of cartilage repair research for decades and continue to be required for regulatory approval for clinical use of biologics, devices, and methods.
This makes rodent models an efficient means for determining mechanisms, assessing variables, and screening drugs, biologics, devices and methods for further investigations in large animal models.
The enduring vision is to explicate the underlying neurobiology, identify new treatment targets, develop drugs, biologics, devices and refined psychosocial interventions for new targets, and do so in a lifespan context that emphasizes early developmental events and is personalized.
In December 2011, the United States Food and Drug Administration FDAA) issued a Guidance for Industry regarding the requirements for approval of drugs, biologics, devices or combination products intended to repair or replace cartilage in the knee.
Ideally, these innovative therapies can complement existing small molecule, biologic and device approaches, forming a so-called fourth pillar of medicine and allowing clinicians to identify the best treatment approach for each patient.
Therefore the purpose of this study was to investigate if a tibial press-fit fixation with a free bone block, as a biologic fixation device near to the joint line, can reduce bone tunnel enlargement in fixation of a soft tissue graft.
For some innovations, their attractiveness is even enhanced by additional professional fees associated with their use; if physicians can earn an additional fee for the procedure accompanying the biologic or device, they effectively become part of the marketing team of the manufacturer.
Upon infusion, they go to work as biologic homing devices, orchestrating a molecular onslaught against the tumor.
